Azithromycin reduces bronchial wall thickening in infants with cystic fibrosis

The efficacy of azithromycin as an anti-inflammatory agent in infants with CF was investigated in the COMBAT-CF study [1]. Children with CF diagnosed by newborn screening were 1:1 randomly assigned to maintenance treatment with azithromycin or placebo from diagnosis until age of three, stratified by site. The primary outcome measure was structural airway disease as assessed on chest computed tomography scans (CTs) by the manual Perth-Rotterdam Annotated Grid Morphometric for CF (PRAGMA-CF) scoring method [2].

Source: Journal of Cystic Fibrosis - April 6, 2024 Category: Respiratory Medicine Authors: Yuxin Chen, Jean-Paul Charbonnier, Eleni-Rosalina Andrinopoulou, Peter D. Sly, Stephen M. Stick, Harm A.W.M. Tiddens, COMBAT-CF Study Group Source Type: research